Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib induction and maintenance study in moderately to severely active ulcerative colitis
2016-000641-31Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Upadacitinib with Placebo (2 arms). Primary endpoint: Clinical remission at Week 8. Started Jul 2016; status: completed.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-000641-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000641-31.